---
title: "Armata Pharmaceuticals | 10-Q: FY2025 Q2 EPS: USD -0.45"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252738015.md"
published_at: "2025-08-12T20:48:18.000Z"
---

# Armata Pharmaceuticals | 10-Q: FY2025 Q2 EPS: USD -0.45

EPS: As of FY2025 Q2, the actual value is USD -0.45.

### Operating Loss

-   Operating loss for the three months ended June 30, 2025, was $6.8 million, compared to $11.9 million for the same period in 2024, representing a decrease of 42.6%.

### Net Loss

-   Net loss for the three months ended June 30, 2025, was $16.3 million, compared to a net income of $9.0 million for the same period in 2024.

### Research and Development Expenses

-   Research and development expenses decreased by $2.1 million, from $8.5 million for the three months ended June 30, 2024, to $6.4 million for the same period in 2025, primarily due to decreased clinical trial costs.

### General and Administrative Expenses

-   General and administrative expenses were $2.6 million for the three months ended June 30, 2025, a decrease from $3.4 million for the same period in 2024.

### Cash Flow

-   Net cash used in operating activities was $14.8 million for the six months ended June 30, 2025, compared to $20.8 million for the same period in 2024.

### Future Outlook and Strategy

#### Core Business Focus

-   Armata Pharmaceuticals, Inc. plans to continue the development of its phage-based therapeutics, focusing on advancing its lead candidates, AP-PA02 and AP-SA02, through clinical trials. The company aims to secure additional funding to support these initiatives and potentially resume clinical development of AP-PA02 for non-cystic fibrosis bronchiectasis.

#### Non-Core Business

-   The company is exploring potential strategic partnerships to further advance its programs and is considering revising its clinical trial protocols to include additional indications for its phage products.

### Related Stocks

- [ARMP.US - Armata Pharmaceuticals](https://longbridge.com/en/quote/ARMP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 谷歌突然发布 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌发布了最新的大模型 Gemini 3.1 Pro，其推理性能较去年发布的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 评测中，Gemini 3.1 Pro 得分 77.1%，显示出强大的推理能力。新模型支持多源数据综合和复杂 | [Link](https://longbridge.com/en/news/276396515.md) |
| 云原生经纪服务提供商 Clear Street 正式撤回 3.51 亿美元美股 IPO | 云原生经纪服务提供商 Clear Street 于本周四正式撤回其 3.51 亿美元的美股 IPO 申请。该公司原计划以每股 26 至 28 美元的价格发行 1300 万股，但一周前已将发行规模缩减 65%。Clear Street 成立于 | [Link](https://longbridge.com/en/news/276421580.md) |
| Copilot+Azure 巩固领先优势 花旗重申微软 “买入” 评级 | 花旗重申对微软的 “买入” 评级，认为其 Copilot 业务动能增强和 Azure 云业务稳健，巩固了在企业级 AI 软件领域的领先地位。分析师 Radke 指出，管理层对投资者关心的竞争格局和资源分配等问题进行了积极回应，缓解了市场担忧 | [Link](https://longbridge.com/en/news/276455595.md) |
| 沃尔玛四季度财报超预期但盈利指引不及预期，CEO 称 “美国低收入家庭只能勉强维持生计” | 沃尔玛 Q4 营收超预期，新财年盈利指引（每股 2.75-2.85 美元）远低于市场预期的 2.96 美元，显示通胀压力下消费者支出不确定性犹存，拖累股价下跌 1.38%。财报印证 K 型” 分化：高收入家庭驱动增长，低收入群体 “钱包吃紧 | [Link](https://longbridge.com/en/news/276398633.md) |
| 特斯拉在美国推出更便宜的 Cybertruck 车型，售价 59990 美元 | 特斯拉在美国推出了售价为 59990 美元的更便宜的 Cybertruck 车型，使其成为最实惠的版本。同时，特斯拉将最贵的 Cybertruck 车型 Cyberbeast 的价格下调至 99990 美元。此次降价还意味着特斯拉将停止豪华 | [Link](https://longbridge.com/en/news/276410759.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.